Cardiovascular Disease Associated With Androgen-Deprivation Therapy: Time to Give It Due Respect
- 10 April 2015
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (11) , 1232-1234
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Androgen-Deprivation Therapy for Nonmetastatic Prostate Cancer Is Associated With an Increased Risk of Peripheral Arterial Disease and Venous ThromboembolismEuropean Urology, 2012
- Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate CancerJournal of Urology, 2010
- Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2010
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31Journal of Clinical Oncology, 2009
- Androgen Deprivation Therapy, Insulin Resistance, and Cardiovascular Mortality: An Inconvenient TruthJournal of Andrology, 2008
- Low Serum Testosterone and Mortality in Older MenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial InfarctionsJournal of Clinical Oncology, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation TherapyJournal of Clinical Oncology, 2006
- Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen‐deprivation therapyCancer, 2005